Drugmakers race to monthly GLP-1 dosing as weight loss drugs show new cancer protection signal

—Pharmaceutical companies are shifting their weight-loss drug development focus from weekly to monthly GLP-1 injections, betting that less frequent dosing will improve patient compliance and open new market segments. Separately, researchers reported that GLP-1 drugs appear to offer protection against certain cancers, adding to the growing list of benefits beyond weight reduction that have made these drugs some of the most closely watched in medicine. Scientists are still working to understand the mechanism behind the apparent anti-cancer effect. Both developments reinforce the centrality of GLP-1 drugs in the next decade of pharmaceutical development.